Articles
Transforming The Life Sciences Supply Chain Through Blockchain
Imagine the Possibilities: What if innovations in the life sciences supply chain kept up with innovations in medicines and treatments?
With many serialization and track & trace regulations in the compliance period, and others (e.g., EU FMD, US DSCSA) on...
Articles
The need of innovation in the injectable business – a CDMO perspective
The world of drug development and manufacturing is undergoing a change. Nowhere is this more evident than in the rapid increase in complex compounds such as biologics.
This change is further compounded with the erosion of the once commanding ‘blockbuster’...
Articles
Speed, Quality and Cost – Leveraging Australia to Expedite Clinical Development
In recent years, the pharmaceutical industry has seen tremendous changes in the way it is expected to deliver new drugs to market: being under increasing pressure to expedite the development of new therapies,to decrease clinical study duration, and to...
Articles
Predicting the future of cancer immunotherapy: Using autoantibody biomarkers to drive safer and more effective treatments
For a number of years now, immunotherapy has been seen as the dawn of a new era, and is the most promising approach to cancer treatment since the use of targeted therapies, making headlines as results for successive novel...
Drug Research
KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
KemPharm, Inc. , a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced the addition of a new product candidate, KP879, which the company plans to develop as an extended-duration, agonist replacement therapy for the...
Drug Research
PANTHERx Specialty Pharmacy and RxCrossroads by McKesson Collaborate to Streamline the Channel for Precision Medicine Therapies
PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy , and RxCrossroads by McKesson, the leading commercial solutions partner for life sciences companies, announced their collaborative program to simplify the channel for precision medicine therapies. Recognizing a...
Drug Research
Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor
Medigene AG announced that it has entered into an exclusive license agreement with Leiden University Medical Center, the Netherlands, for worldwide rights to develop, manufacture, and commercialize an HA-1-specific T cell receptor (TCR) as a targeted immunotherapy for cancer....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
